NOVARTIS-CENA713D1301

Study Sponsor: Novartis

Study Title

A 24-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Evaluation of the Efficacy, Safety, and Tolerability of the Once-daily Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease (MMSE 10-20)

Medicine or Vaccine (generic name)

rivastigmine

Sponsor Identification Number

CENA713D1301

Trial Registry Identification Number(#'s)

NCT00423085

Medical Condition

Alzheimer's Disease

Phase

Phase 3

Link to study details on the Novartis Clinical Study Register

https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=4162

Link to study details on ClinicalTrials.gov (if available)

https://clinicaltrials.gov/show/NCT00423085

Link to study details on EudraCT (if available)

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

Date Added to this Site

June 2016